Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited

Yapan Bio Private Limited specializes in technology advancement, characterization, and phase I and II GMP production services for vaccines and biologics.

Piramal Pharma Ltd. has completed the acquisition of an incremental 40.67% stake in Yapan Bio Private Limited, a Hyderabad-based CDMO specializing in vaccines and biologics, for an aggregate cash consideration of ₹76 crore, or $7.95M USD. As a result of this transaction, PPL now owns 74% of Yapan Bio’s equity, making Yapan Bio a subsidiary of PPL.

Finalized in August 2026, the acquisition marks a consequence step forward in PPL’s long-range plan to increase its presence in the biologics sector. With the completion of this deal, PPL will fully embed the subsidiary’s well-developed large molecule capabilities into its integrated solution providing, allowing the Company to offer customers wider services in the space and increasing its capability to develop and scale complex biologic therapies with greater effectiveness. The subsidiary continues to operate within the structure of Piramal Pharma Solutions (PPS), the CDMO arm of PPL.

Yapan Bio also directly supports ADCelerate PPS’s fixed-price, combined platform that rationalizes Phase I ADC development from R&D to GMP in as little as 12 months. This acquisition further positions ADCelerate and reinforces PPL’s ability to deliver life-saving ADCs to market with speed and consistency.

“This strategic investment doesn’t just fuel our long-term growth; it also puts Patient Centricity into action,” said Peter DeYoung, CEO, Piramal Global Pharma. “By integrating Yapan Bio’s specialized expertise into our global network, we’re empowering our partners to meet a rising global demand for complex biologics and helping patients worldwide secure continued access to the therapies they need.”

According to Towards Healthcare, the oral solid dosage contract manufacturing market is projected to grow significantly, with estimates indicating the market size will increase from USD 43.65 billion in 2026 to approximately USD 75.26 billion by 2035, expanding at a CAGR of 6.24% from 2026 to 2035. Oral solid dose (OSD) production is a significant part of pharmaceutical manufacturing, responsible for manufacturing the most common dose forms prescribed nowadays. From tablets and capsules to soft gels and gummies, oral solid dosage forms are a tried-and-true process of drug delivery, with a history that spans nearly two centuries. Oral solid dosage (OSD) contract manufacturing allows drug organizations to outsource tablet and capsule manufacturing to specialized collaboration. Significant advantages involves reduce capital expenses, rapid access to advanced technologies such as modified-release coatings, expert regulatory compliance, and the ability to focus internal teams on core therapeutic research.

About Piramal Pharma Solutions

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) providing end-to-end advancement and manufacturing services in the drug life cycle. This companies serve consumer via a worldwide integrated network of services in North America, Europe, and Asia. This allows companies to provide a comprehensive range of services involving drug discovery services, process and pharmaceutical advancement services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. This company provides specialized solutions like the advancement and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and solutions, and potent solid oral therapeutic products. PPS provides development and manufacturing solutions for biologics involving vaccines and gene therapies, made possible via Piramal Pharma Limited’s subsidiary, Yapan Bio Private Limited.

About Piramal Pharma Limited

Piramal Pharma Limited provides a portfolio of differentiated products and services via its 17 worldwide development and production facilities and a worldwide distribution network in over 100 countries. PPL involves Piramal Pharma Solutions (PPS), a combined contract development and manufacturing organization; Piramal Critical Care (PCC), a challenging hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. Furthermore, one of PPL’s associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has evolved as one of the market leaders in the ophthalmology therapy region in the Indian pharma market.

A recent report by Towards Healthcare highlights that the oral solid dosage contract manufacturing market is growing, as contract development and production organizations, such as UPM Pharmaceuticals, reduce challenges for developers while enabling them to focus on core research and well-developed competencies.  Advantages of working with an oral solid dosage drug manufacturing organization include streamlining the development process, providing more flexible manufacturing, offering access to experts, helping mitigate challenges, and lowering the requirement for in-house resources. The oral solid dosage form is preferred for its simplicity of administration, stability, and affordability, creating it the preferred standard for a broad range of therapeutic applications.